RAY B Stock Overview
A medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for RAY B from our risk checks.
RaySearch Laboratories AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 125.60 |
52 Week High | SEK 155.00 |
52 Week Low | SEK 63.00 |
Beta | 1.25 |
11 Month Change | -9.51% |
3 Month Change | -1.41% |
1 Year Change | 75.66% |
33 Year Change | 53.55% |
5 Year Change | -4.56% |
Change since IPO | 22,064.97% |
Recent News & Updates
Recent updates
RaySearch Laboratories AB (publ) (STO:RAY B) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable
May 21The Returns At RaySearch Laboratories (STO:RAY B) Aren't Growing
May 11RaySearch Laboratories (STO:RAY B) Will Want To Turn Around Its Return Trends
Oct 04Does RaySearch Laboratories (STO:RAY B) Have A Healthy Balance Sheet?
Jul 10Is RaySearch Laboratories (STO:RAY B) Using Too Much Debt?
Nov 17One Forecaster Is Now More Bearish On RaySearch Laboratories AB (publ) (STO:RAY B) Than They Used To Be
Mar 15Is RaySearch Laboratories (STO:RAY B) A Risky Investment?
Feb 22Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?
Nov 04Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?
Mar 30What Kind Of Shareholders Hold The Majority In RaySearch Laboratories AB (publ)'s (STO:RAY B) Shares?
Feb 23Shareholder Returns
RAY B | SE Healthcare Services | SE Market | |
---|---|---|---|
7D | -9.8% | -5.0% | -7.2% |
1Y | 75.7% | 39.6% | 10.7% |
Return vs Industry: RAY B exceeded the Swedish Healthcare Services industry which returned 37.9% over the past year.
Return vs Market: RAY B exceeded the Swedish Market which returned 9.9% over the past year.
Price Volatility
RAY B volatility | |
---|---|
RAY B Average Weekly Movement | 5.5% |
Healthcare Services Industry Average Movement | 5.5% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: RAY B has not had significant price volatility in the past 3 months.
Volatility Over Time: RAY B's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 398 | Johan Lof | www.raysearchlabs.com |
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. It develops and markets RayStation, a treatment planning system for radiation therapy; RayCare, an oncology information system that manages clinical activities; RayIntelligence, a cloud-based analytics system for monitoring and enhancement of cancer therapy; and RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems. The company offers RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, and electron beam radiation therapy; and µ-RayStation, a software platform for planning and evaluation in small animal irradiation research.
RaySearch Laboratories AB (publ) Fundamentals Summary
RAY B fundamental statistics | |
---|---|
Market cap | SEK 4.31b |
Earnings (TTM) | SEK 100.71m |
Revenue (TTM) | SEK 1.05b |
42.8x
P/E Ratio4.1x
P/S RatioIs RAY B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RAY B income statement (TTM) | |
---|---|
Revenue | SEK 1.05b |
Cost of Revenue | SEK 105.76m |
Gross Profit | SEK 943.42m |
Other Expenses | SEK 842.72m |
Earnings | SEK 100.71m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 16, 2024
Earnings per share (EPS) | 2.94 |
Gross Margin | 89.92% |
Net Profit Margin | 9.60% |
Debt/Equity Ratio | 0% |
How did RAY B perform over the long term?
See historical performance and comparison